medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis: a mathematical modeling analysis

January 24, 2024

Lyndon P. James,[1,2] Fayette Klaassen,[3] Sedona Sweeney,[4] Jennifer Furin,[5] Molly F. Franke,[5] Reza Yaesoubi,[6] Dumitru Chesov,[7,8] Nelly Ciobanu,[9] Alexandru Codreanu,[9] Valeriu Crudu,[9] Ted Cohen,[10] Nicolas A. Menzies[2,3]

Affiliations:

1. PhD Program in Health Policy, Harvard University, Cambridge, MA, USA
2. Center for Health Decision Science, Harvard T. H. Chan School of Public Health, Boston, MA, USA
3. Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA, USA
4. Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK
5. Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA
6. Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA
7. Discipline of Pneumology and Allergology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova
8. Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
9. Chiril Draganiuc Institute of Phthisiopneumology, Chisinau, Moldova
10. Department of Epidemiology and Microbial Diseases, Yale School of Public Health, New Haven, CT, USA

Corresponding author: LPJ
Corresponding author email: lyj519@mail.harvard.edu

ABSTRACT

Background: Emerging evidence suggests that shortened, simplified treatment regimens for rifampicin-resistant tuberculosis (RR-TB) can achieve comparable end-of-treatment outcomes to longer regimens. We compared a 6-month regimen containing bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) to a standard of care strategy using a 9- or 18-month regimen depending on whether fluoroquinolone resistance (FQ-R) is detected on Drug Susceptibility Testing (DST).

Methods and Findings: The primary objective was to determine whether 6 months of BPaLM is a cost-effective treatment strategy for RR-TB. We used genomic and demographic data to parameterize a mathematical model estimating long-term health outcomes measured in quality-adjusted life years (QALYs) and lifetime costs in 2022 USD ($) for each treatment strategy for patients 15 years and older

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

diagnosed with pulmonary RR-TB in Moldova, a country with a high burden of TB drug resistance. For each individual, we simulated the natural history of TB and associated treatment outcomes, as well as the process of acquiring resistance to each of 12 anti-TB drugs. Compared to the standard of care, 6 months of BPaLM was cost-effective. It was estimated to reduce lifetime costs by $3,366 (95% UI: [1465, 5742] p<0.001) per individual, with a non-significant change in QALYs (-0.06; 95% UI: [-0.49, 0.032] p=0.790). For those stopping moxifloxacin under the BPaLM regimen, continuing with BPaL plus clofazimine (BPaLC) provided more QALYs at lower cost than continuing with BPaL alone. 6 months of BPaLM had at least a 93% chance of being cost-effective, so long as BPaLC was continued in the event of stopping moxifloxacin. 6 months of BPaLM reduced the average time spent with TB resistant to amikacin, bedaquiline, clofazimine, cycloserine, moxifloxacin and pyrazinamide, while it increased the average time spent with TB resistant to delamanid and pretomanid. Sensitivity analyses showed 6 months of BPaLM to be cost-effective across a broad range of values for the relative effectiveness of BPaLM, and the proportion of the cohort with FQ-R. Compared to the standard of care, 6 months of BPaLM would be expected to save Moldova's national TB program budget $7.1 million (95% UI: [1.3 million, 15.4 million] p=0.002) over the five year period from implementation. This analysis did not account for all possible interactions between specific drugs as they apply to treatment effectiveness, to resistance acquisition, or to the consequences of specific types of severe adverse events, nor did it model how the intervention may affect the transmission dynamics of RR-TB.

Conclusions: Compared to the standard of care, the implementation of the 6-month BPaLM regimen could improve the cost-effectiveness of care for individuals diagnosed with RR-TB, particularly in settings where current long-course regimens are challenging to implement and afford. Further research may be warranted to explore the suitability of shorter RR-TB regimens in specific national settings.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

AUTHOR SUMMARY

Why was this study done?

- Drug resistance poses a major barrier to the effective treatment of tuberculosis, especially in Moldova and other post-Soviet states which have the highest levels of resistance in the world.

- Individuals with tuberculosis resistant to the key drug rifampicin face a worse prognosis, a longer and more expensive course of treatment, and more side effects than individuals with rifampicin-susceptible tuberculosis.

- Until recently, the standard of care for rifampicin-resistant tuberculosis involved many drugs in combination, often given for 18 months or longer.

- The newer, 6-month "BPaLM" regimen is comprised of four drugs (bedaquiline, pretomanid, linezolid, moxifloxacin) to which resistance levels are currently low, and while it was shown to be just as effective as the standard of care for 72-week health outcomes, its effect on lifetime health outcomes, costs, and the acquisition of drug resistance was less clear.

What did the researchers do and find?

- Using a mathematical model, we projected the lifetime health benefits and costs of the 6-month BPaLM regimen as compared to the standard of care treatments for rifampicin-resistant tuberculosis, and found that 6 months of BPaLM provided similar health benefits to longer regimens, at lower cost.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- Compared to the standard of care, we also found that the 6-month BPaLM regimen shortened the average duration of tuberculosis that was resistant to the drugs amikacin, bedaquiline, clofazimine, cycloserine, moxifloxacin, and pyrazinamide, while it increased the average duration of tuberculosis resistant to delamanid and pretomanid.

- For individuals receiving BPaLM who had to stop taking the drug moxifloxacin, we found that it would be beneficial on both health and cost grounds to replace it with clofazimine, thereby topping the regimen back up to four drugs.

What do these findings mean?

- Using conventional benchmarks for value-for-money, 6 months of BPaLM is a cost-effective approach for the treatment of rifampicin-resistant tuberculosis in Moldova, and potentially other post-Soviet countries.

- Though the effect of the 6-month BPaLM regimen on the spread of drug resistance in the population is uncertain and not addressed directly by this study, this combination of newer drugs appears to achieve cure more quickly, which reduces the amount of time an individual is potentially infectious and so may be beneficial in fighting resistance to several drugs, even while it may increase the spread of resistance to others.

- Further studies may be warranted to explore how well these findings translate to different global regions where health system capabilities, costs, and existing resistance patterns may differ.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

INTRODUCTION

Treatment for rifampicin-resistant tuberculosis (RR-TB) is complex, involving combinations of several drugs—many of which have substantial potential for toxicity—over a prolonged course of therapy. The 2022 WHO Guidelines for the treatment of drug-resistant tuberculosis recommend a shorter, 6-month regimen composed of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) to treat rifampicin-resistant tuberculosis (RR-TB) [1]. These guidelines updated earlier 2020 WHO Guidelines that recommended several treatment regimens, each comprising 4-7 drugs for 9-18 months or longer [2].

The evidence base for shorter regimens for RR-TB has been broadly positive, including results from observational studies [3,4], single-arm clinical trials [5,6], mathematical modeling analyses [7], and the recent multicenter open-label randomized controlled trial TB-PRACTECAL [8]. Although trial recruitment was stopped early on the recommendation of a planned, interim review by the study monitoring committee, the analysis suggested that 6 months of BPaLM was non-inferior to the standard of care with respect to treatment outcome (a composite of death, treatment failure, treatment discontinuation, loss to follow-up, or recurrence) and was beneficial with respect to safety [8]. The adoption of shorter, simplified regimens may be further bolstered by the forthcoming publication of the results of the endTB trial [9–13], but the absence of larger, confirmatory trials led to a conditional recommendation by the WHO in 2022. The pursuit of effective shorter treatment regimens is also driven by the desire to alleviate the considerable psychological and emotional toll of prolonged treatment for RR-TB. On top of drug side effects [14], many patients undergoing treatment for RR-TB experience stigma, depression, loss of self-esteem, and economic hardship from an inability to work [15]. Patients may lack access to sufficient psychological and financial supports [16–18], and this may be particularly hard for individuals with housing or employment instability, or substance use disorder [19].

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

The 2020 WHO Guidelines represent the existing standard of care in many settings. In addition to higher prices and supply constraints for newer drugs [20],[21], it is expected that the rollout of the BPaLM regimen as part of the newer 2022 Guidelines may be delayed by concerns about comparative effectiveness and cost-effectiveness [20–24]. Implementation may also be met with concern over the emergence of drug resistance, particularly in settings with limited capacity to detect resistance to newer agents such as bedaquiline, pretomanid, and linezolid [25]; such capacity constraints are multifactorial, from the expense of investing in new technologies and associated laboratory workforce development, to supply chain interruptions and divergent political priorities [26,27]. The decision to implement the new 6-month BPaLM regimen will depend on setting-specific tradeoffs between regimen effectiveness, cost, the complexity of treatment decisions, and existing levels of resistance to anti-TB drugs in the population. Decision analysis provides a framework to analyze these tradeoffs, and a recent cost-effectiveness study using evidence from TB-PRACTECAL found that 6-months BPaLM may reduce cost and improve health relative to the standard of care in several countries [28]. Our analysis builds on this work by focusing on longer term outcomes that are difficult to measure in a trial setting and by examining a wider range of testing and treatment approaches, including whether patients who must stop moxifloxacin—due to side effects or acquired resistance—should continue on BPaL alone, or BPaL plus clofazimine (BPaLC) [25,28].

In this study, we investigated the health impact and cost-effectiveness a 6-month BPaLM regimen for the treatment of adults with pulmonary RR-TB, as compared to the standard of care. We considered a range of treatment strategies incorporating these two approaches, varying the timing and frequency of drug susceptibility testing (DST) as well as how regimens would be modified for individuals developing fluoroquinolone resistance. To estimate outcomes, we used a Markov microsimulation model parameterized with detailed genomic sequencing data describing specific patterns of initial drug resistance, and calculated the effect of each treatment strategy on length and quality of life as well as

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

costs, accounting for regimen effectiveness, risks of severe adverse events (SAEs) due to drug toxicity, and acquisition of resistance.

We conducted the analysis for the setting of Moldova, an upper-middle income post-Soviet country where the incidence rate of RR-TB is among the highest in the world, and where an estimated 33% of individuals newly diagnosed with TB have RR-TB, ten times higher than the same proportion globally [29,30]. The reasons for this picture are not fully understood, but it is thought that economic shocks following the breakup of the Soviet Union contributed to this picture in the region, along with early treatment discontinuation [31] and mass incarceration [32]. In recent years in Moldova, a multidisciplinary committee reviews the treatment course of every patient receiving treatment for RR-TB, and WHO treatment guidelines are closely adhered to [VC, DC]. Moldova also has developed a robust TB laboratory infrastructure, which provided a platform for recent genomic sequencing of culture-positive isolates [33]. By harnessing this genomic resistance data, we hope to improve the cost-effectiveness of treatment in a country with a very high burden of RR-TB, as well as other countries in the region. We also explored the generalizability of our findings to settings with a different prevalence of initial fluoroquinolone resistance among RR-TB.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

METHODS

Strategies

We compared eight treatment strategies, each reflecting a different approach to drug regimen choice and timing of DST (Table 1). Two strategies adopted drug regimens aligned with the standard of care as defined by the 2020 WHO Guidelines [2], with all individuals started on a WHO longer regimen while awaiting the results of second-line DST by mycobacterial growth indicator tube (MGIT) to fluoroquinolones and injectables. Fluoroquinolone resistance (FQ-R) identified via MGIT was assumed to result in the continuation of an 18-month WHO longer regimen, with refinements as necessary based on DST. If fluoroquinolone susceptibility (FQ-S) was detected, treatment was switched to a 9-month regimen (S1 Fig). Under one standard of care strategy (strategy (7)), we modelled the minimum guideline-recommended frequency of second-line DST–every 4 months, and in another (strategy (8)) we increased this to a monthly frequency. While the 2020 WHO Guidelines did not prescribe exactly one combination of drugs for each scenario, we adopted a single combination of drugs for each situation for tractability, based on our best interpretation of the guideline's hierarchy of group A, B, and C drugs (S1 Fig).

The remaining six strategies were modeled on the 2022 WHO Guidelines [34] with 6-month BPaLM-based regimens. In three of these strategies, individuals having to stop Moxifloxacin (because of a SAE or because resistance was detected on DST) were continued on BPaL alone, as recommended by the 2022 Guidelines. In the remaining three, they continued on BPaLC. The remaining differences between these six strategies depended on the prescribed schedule of DST to second-line drugs; in two of these strategies, we explored the effects of omitting routine second-line DST at treatment initiation (Table 1).

Table 1. **Key features of the modeled RR-TB treatment strategies.**

Strategy No.	Guidelines informing the strategy	Drug regimen	Regimen duration	For BPaLM-based strategies only, prescribed regimen for those who discontinue Moxifloxacin	Replacement drugs, in order, for all other discontinuations	DST for second-line drugs (MGIT) at treatment initiation	Routine frequency of subsequent DST for second-line drugs	Indications for drug discontinuation	Length of regimen extension, if necessary*
1	2022 WHO Guidelines	BPaLM	6 months	BPaLC	Clofazimine, Cycloserine	Yes	4 months	Immediately following: • Resistance identified on DST • Grade 4-5 Severe Adverse Event	6 months
2	2022 WHO Guidelines	BPaLM	6 months	BPaLC		Yes	1 month		
3	2022 WHO Guidelines	BPaLM	6 months	BPaL		Yes	4 months		
4	2022 WHO Guidelines	BPaLM	6 months	BPaL		Yes	1 month		
5	2022 WHO Guidelines	BPaLM	6 months	BPaLC		No	4 months		
6	2022 WHO Guidelines	BPaLM	6 months	BPaL		No	4 months		
7	2020 WHO Guidelines (standard of care)	Start treatment with WHO Longer regimen (bedaquiline, clofazimine, linezolid, moxifloxacin), await second-line DST. **<u>If FQ-R,</u>** continue on WHO Longer regimen, i.e.:				Yes	4 months		
		Bedaquiline, Clofazimine, Linezolid, Cycloserine	18 months	n/a	Ethambutol, Delamanid, Pyrazinamide, Amikacin, Ethionamide				
		<u>If FQ-S,</u> switch to 2020 WHO shorter, all-oral bedaquiline containing regimen:							
		Bedaquiline, Clofazimine, Ethambutol, Ethionamide, Isoniazid, Moxifloxacin, Pyrazinamide	9 months	n/a	Delamanid, Cycloserine				
8	2020 WHO Guidelines (standard of care)	As for Strategy No. 7				Yes	1 month		

BPaL – bedaquiline, pretomanid, linezolid; BPaLC – bedaquiline, pretomanid, linezolid, clofazimine; BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin; DST – drug susceptibility test; FQ-S – fluoroquinolone susceptible; FQ-R – fluoroquinolone resistant; MGIT – mycobacterial growth indicator tube; WHO – World Health Organization

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

*Regimen extensions were implemented for those who had not yet successfully completed treatment. While the 2020 WHO Guidelines recommended the BPaL regimen in specific situations, none of the modeled cohort met the inclusion criteria to receive BPaL under those strategies.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Population and data

We modeled a cohort of individuals aged 15 years and older diagnosed with RR-TB in Moldova. For each individual, their age and the resistance profile of the strain of *M. tuberculosis* causing infection were informed by publicly available genomic sequencing data from Moldova [35]. These data comprised single-strain *M. tuberculosis* samples collected in 2018–2019; a full description has been provided by Yang and colleagues [30]. We assumed that a mutation associated with resistance conferred full resistance to that drug. Conversely, *M. tuberculosis* strains lacking relevant resistance mutations were assumed to be fully susceptible to the respective drugs. We excluded data for rifampicin susceptible strains (S2 Fig) leaving 674 distinct samples from which we simulated the modeled population. The proportion of isolates with resistance to each drug is shown in S3 Fig. This analysis used publicly available data only, and did not require ethical approval.

Model

We used a Markov microsimulation model to simulate lifetime outcomes for a cohort of 10,000 individuals. Individuals in the model were simulated by random draws from the genomic sequencing dataset, with replacement. They were each assigned a drug regimen based on the modeled strategy (Table 1). Individuals then were assumed to transition between four health states: (1) Receiving TB treatment, (2) TB disease – not receiving treatment, (3) Cured post-treatment, and (4) Dead (S4 Fig). Within each Markov state, individual events were tracked including true cure as a result of treatment or self-cure, the occurrence of SAEs, second-line DST, changes to the drug regimen, loss to follow-up, relapse, death, and the evolution of drug resistance for that individual's strain of *M. tuberculosis*. Extensions to the treatment regimen were implemented for those not observed to have successfully completed treatment.

While the range of SAEs resulting from TB treatment are of many varying durations and degrees of impact on quality of life, we accounted for these events in a simplified way by modeling the risk of a

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

grade 4-5 SAE during the first three months of exposure to each drug, with each grade 4-5 SAE conferring a small but lifelong deduction in quality of life (Table 2, S1 Table). Grade 4-5 SAEs and diagnosed resistance constituted lifetime contraindications to the relevant drug, and replacements were made according to the modeled strategy (Table 1).

1 **Table 2. Key model parameters.**

Parameter	Point Estimate	Distribution	Source(s)	Notes
Rate of death from untreated TB, annual	0.389	Published point estimate (median) and 95% CrI (0.335-0.449) modeled as Lognormal (mu -0.9442, sigma 0.0763)	Ragonnet R, et al. Clin Infect Dis 2020 [36]	Applied to those with TB who are no longer receiving treatment (i.e., those LTFU and those who appeared to successfully complete treatment but had not been truly cured).
Mortality rate ratio for those who are cured, compared to background mortality	3.070	Published point estimate and 95% CI (2.12, 4.45) modeled as Lognormal (mu 1.122, sigma 0.1889)	Romanowski K., et al. Lancet Infect Dis 2019 [37]	Estimate for pulmonary TB.
Rate of self-cure, annual	0.231	Published point estimate and 95% CrI (0.177, 0.288) modeled as Lognormal (mu -1.465, sigma 0.136)	Ragonnet R, et al. Clin Infect Dis 2020 [36]	Applied to those no longer receiving treatment (i.e., those LTFU and those who appeared to successfully complete treatment but had not been truly cured) and the first two months of treatment.
Probability of all-cause death for WHO longer regimen, MDR only (excluding XDR), at 21 months	0.080	N/A	Bastos M. L., et al. 2017 [38]	To convert to a monthly estimate for disease-specific mortality, we assumed a 21 month regimen duration. Further detail in S2 Appendix.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Parameter	Point Estimate	Distribution	Source(s)	Notes
Mortality rate among those who are not cured but on treatment, MDR-TB only (excluding XDR-TB), monthly	0.00536	Beta (mean 0.00536, s.d. 0.00178)*	Bastos M. L., et al. 2017 [38]	See S2 Appendix.
Probability of observed success for a fully effective WHO longer regimen, MDR-TB only (excluding XDR), at 21 months	0.640	Published point estimate and 95% CI (0.63-0.65) modeled as Beta (mean 0.64, s.d. 0.0051	Bastos M. L., et al. 2017 [38]	To convert to a monthly cure rate for Standard of Care strategies, we assumed a 21 month regimen duration. We used this parameter specifically to inform the effectiveness of a *fully effective* regimen of 4 drugs (i.e., a regimen composed of 4 drugs to which the individual's strain of *M.tb.* is truly susceptible). See also S2 Appendix.
Hazard Rate Ratio of cure for each effective drug in the regimen (relative to one fewer effective drugs)	1.65	Published point estimate and 95% CI (1.48, 1.84) modeled as Lognormal (mu 0.5008, sigma 0.056)	Yuen, CM. et al. PLoS Med 2015 [39]	Applied to a maximum of 4 drugs (i.e., there is no further increase in the monthly cure rate for 5 drugs compared to 4).
Hazard Rate Ratio of cure for the BPaLM regimen as compared to the SOC	1.59	Published point estimate and 95% CI (1.18, 2.14) modeled as Lognormal (mu 0.453, sigma 0.147)	Nyang'wa, B.-T. et al. 2022 [8]	The referenced estimate is based on the outcome of time to sputum culture conversion. We assume the same relationship holds for the rate of true cure, and explore this assumption in sensitivity analysis.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Parameter	Point Estimate	Distribution	Source(s)	Notes
Probability of acquiring resistance to a drug, conditional on treatment with a regimen of 4 or more effective drugs, over 6 months	0.008	Published point estimate and 95% CI (0.005, 0.01) modeled as Beta (mean 0.008, s.d. 0.0015)	Lew W. et al. Annals Intern Med 2008 [40]	We define an "effective" drug as one to which the strain of *M. tuberculosis* is susceptible. We use the published estimate to produce a monthly rate of resistance acquisition, which is constant conditional on the number of effective drugs.

BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin, CI – confidence interval; CrI – credibility interval; LTFU – lost to follow up; M. tb. – mycobacterium tuberculosis; MDR – multidrug-resistant; NHB – Net Health Benefit; QALY – Quality-adjusted Life Year; RR-TB – rifampicin-resistant tuberculosis; TB – tuberculosis; UI – Uncertainty Interval; USD – United States Dollars; WHO – World Health Organization; WTP – Willingness-to-Pay; XDR – extensively drug resistant.

Please see S1 Table for the full set of model parameter descriptions, and S2 Table for the probabilities of loss to follow up by month of treatment.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Each month, we tracked the drug regimen and the true resistance profile of each individual's strain of *M. tuberculosis*. The number of effective drugs in a regimen was defined as the sum of all drugs being received, minus those drugs to which the strain of *M. tuberculosis* was resistant. The effect estimate for cure in BPaLM-based strategies as compared to the standard of care was modeled as the trial estimate for sputum culture conversion from TB-PRACTECAL, conditional on the number of effective drugs in the regimen, up to a maximum of four (i.e., four effective drugs confer a higher monthly cure rate than three, but five or more effective drugs do not confer a higher monthly cure rate than four) [8]. We varied this parameter in sensitivity analysis. S3 Fig displays the modeled rate of acquisition of new resistance to each drug, which was also conditioned on the number of effective drugs, to a maximum of four. S1 Table details the derivation and values for these and all other model parameters. DST was performed at a frequency informed by the strategy (Table 1), with sensitivity and specificity incorporated for each (S1 Table). Additional detail on model structure is provided in the S1 Appendix.

Outcomes

The primary health outcome was measured in quality-adjusted life years (QALYs), a conventional approach in cost-effectiveness analysis [41,42]. QALYs measure the total length of time lived, weighted by time-varying, health-related quality of life, where 1 QALY is valued equivalently to one year in a state of perfect health [42,43]. This approach integrates the effects of the treatment strategies on both length and quality of life. QALYs rely on several assumptions, including risk-neutrality over length of life, and that maximizing total population QALYs—summed across all individuals—is desirable [44]. For each modeled individual in each month, we assigned health-related quality of life weights on a scale from 0 (dead) to 1 (perfect health), and multiplied the weight by 1/12 to account for the one-month cycle length (i.e., a dead individual accrued 0 QALYs for that month, and an individual in perfect health accrued 1/12 QALYs). These estimates were lowest on average at presentation and increased during the course of treatment; grade 4-5 SAEs also conferred a decrement in the utility weight (S1 Table). The total QALYs

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

were calculating by summing all the month-specific QALYs accrued over each modeled individual's lifetime.

We measured the impact on drug resistance by summing for each individual, and for each of 12 anti-TB drugs, the number of months they experienced TB disease with resistance to that drug. We then calculated three summary measures for the impact on drug resistance. In the first, we calculated the mean duration with resistance to each drug for the entire cohort by aggregating the time with resistance across the whole cohort for each drug, then dividing by the size of the starting cohort. Second, we calculated the mean duration of *untreated* TB disease with resistance to each drug by summing the time with resistance only among those individuals in Markov state (2)—TB disease no longer receiving treatment—and again averaging across the starting cohort. These measures were designed to reflect the relevance of the policies for the transmission of drug resistance . We calculated both because—for individuals no longer receiving treatment—there could be a higher risk that *M. tuberculosis* will transmit to another host, compared to the cohort as a whole. Third, we calculated the lifetime cumulative incidence of acquiring resistance to each drug, per individual in the cohort.

As a set of secondary health outcomes, we calculated the number of grade 4-5 SAEs experienced per patient to each of the drugs, and total life years (LYs, i.e. not weighted by health-related quality of life). To permit the validation of our model results, we also tracked two types of shorter-term outcomes at 6 months, 12 months, and 17 months (i.e., 72 weeks, the trial endpoint in TB-PRACTECAL): a) the proportion of individuals experiencing the end-of-treatment outcomes of Success, Failed by Treatment, Lost to Follow-up (LTFU), and Dead, as would typically be reported programmatically to the WHO; and b) a composite unfavorable outcome, including Death, LTFU, failed by treatment, and grade 4-5 SAEs, based on the primary outcome in TB-PRACTECAL [8].

We measured the total costs under each strategy from a societal perspective in 2022 United States dollars ($) as the sum of direct medical, direct non-medical, and indirect costs accruing in each period. Direct medical costs (i.e., those arising directly from the consumption of healthcare goods and services) were

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

calculated by adding the costs of the drugs received, laboratory culture and DST to second-line drugs, a baseline healthcare resource utilization in the form of inpatient and outpatient services, and the cost of LTFU tracing. Direct non-medical and indirect costs were informed by published estimates for Moldova [45]. Each grade 4-5 SAE was accompanied by a utilization cost for inpatient and outpatient services. Direct non-medical costs (e.g., transportation) and indirect costs (e.g., productivity losses) accrued for every additional month on treatment. The indirect costs also accrued for those LTFU prior to cure. Productivity losses secondary to early mortality were not included in total costs, and were calculated separately.

Undiscounted values were calculated for all outcomes. For QALYs and total costs only, discounted values were also calculated using an annual discount rate of 3%.

Cost-effectiveness analysis

First, we ruled out dominated strategies (i.e., those strategies that were both more expensive and provided fewer QALYs on average than a linear combination of other strategies. We then calculated the relevant incremental cost-effectiveness ratios (ICER; a measure of the additional cost required to produce one additional QALY, as compared to the next cheapest, non-dominated strategy). We identified the cost-effective strategy as that with the greatest health gains, subject to the constraint that— in order to provide value for money—the ICER must be below the willingness-to-pay (WTP) threshold [41,46]. Lower ($4700 per QALY) and higher ($7021 per QALY) benchmarks for these thresholds in Moldova were based on published estimates using an opportunity cost approach [47], updated to 2022 USD (S1 Table). As ICERs may be challenging to interpret in some cases [48], we also calculated the Net Health Benefit (NHB) of each strategy (see S1 Appendix), with the cost-effective strategy identified as that with the highest NHB [41]. This is mathematically equivalent to the ICER approach. The CHEERS checklist is included in S1 Checklist [49].

Budget Impact

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

In order to account for the effect of implementing 6-months of BPaLM on the national TB program budget in Moldova, we tracked the subset of aforementioned cost outcomes borne by the TB program. We organized these costs under the following categories: drugs, laboratory tests, routine inpatient and outpatient care, and non-routine inpatient and outpatient care (i.e., care stemming from the treatment of grade 4-5 SAEs, for adjustment of a regimen following the detection of resistance on DST, or for LTFU tracing). The estimated budget impact was calculated for each year over a five year period, scaled to the annual number of case notifications of RR-TB in Moldova.

Statistical analysis

We estimated results via individual-level microsimulation, with lifetime outcomes for each of 10,000 individuals simulated for each of the diagnostic and treatment strategies described above.

Sensitivity analyses

Probabilistic Sensitivity Analysis (PSA) was conducted to account for uncertainty by constructing distributions for model input parameters (S1 Table). In a second-order Monte Carlo simulation, we drew 1,000 parameters sets from the distributions. For each parameter set, the 10,000 individuals were simulated through each strategy, and a set of results was calculated. Finally, point estimates for each outcome were calculated as the mean of these 1,000 second-order simulations, and 95% uncertainty intervals (UIs) were constructed using the 2.5^{th} and 97.5^{th} centiles [50]. Point estimates and 95% UIs were also calculated for the differences between leading 6 month BPaLM-based and SOC-based strategies, and p-values were constructed from the empirical cumulative distribution function of those differences. Further detail is provided in the S1 Appendix.

Some important model parameters have substantial uncertainty. We performed one-way sensitivity analyses on two of these key inputs to understand the relationship with study outcomes. First, we varied the main effect estimate for cure across the uniform distribution (1.00, 2.14). Next, we varied the prevalence of fluoroquinolone resistance among individuals with diagnosed RR-TB across the uniform

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

distribution (0%, 40%) to aid the generalization of results to settings with a different prevalence of fluoroquinolone resistance.

Validation

We validated the modeled end-of-treatment (EOT) outcomes to estimates reported to WHO over the period 2010-2019. We also validated the composite of unfavorable outcome at 72 weeks against the findings of TB-PRACTECAL [8]. Further detail is provided in the S1 Appendix.

Software

The simulation was conducted in TreeAge Pro Healthcare 2023 [51] and figures were made in R [52] using several packages [53–61]. TreeAge and R code files are available in a repository.[62]

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

RESULTS

Health effects, costs, and cost-effectiveness

Health effects, costs, and cost-effectiveness results for all strategies are presented in Table 3 and Fig 1. Among the 6-month BPaLM strategies, the highest health benefits were achieved by Strategy (1) (BPaLC if Mfx stopped, second-line DST upfront, then repeated at 4 monthly intervals), with undiscounted QALYs of 14.75 (95% UI: [12.76, 16.54]). The two standard of care strategies (Strategies (7) and (8)) both produced slightly more QALYs than Strategy (1), with less than 0.01 undiscounted QALYs between them on average. The Life Years (unadjusted for health-related quality of life) obtained under each strategy are displayed in S3 Table.

Table 3. Costs, health impacts, and cost-effectiveness of RR-TB treatment strategies.

STRATEGY DESCRIPTION				COST		HEALTH IMPACT		COST-EFFECTIVENESS				
Strategy Name	**Alternative regimen if Mfx stopped (2022 Guidelines only)**	**2nd line DST at treatment initiation**	**Routine frequency of subsequent 2nd line DST**	**Undiscounted Total Cost (2022 USD)**	**Discounted Total Cost (2022 USD)**	**Undiscounted QALYs**	**Discounted QALYs**	**Incremental Discounted Total Cost (2022 USD)**	**Incremental Discounted QALYs**	**Incremental Cost-effectiveness Ratio**	**NHB, lower bound WTP (QALYs)**	**NHB, upper bound WTP (QALYs)**
(5) 6 months BPaLM	BPaLC	No	Every 4 months	8,412 (6,469, 10,974)	8,153 (6,279, 10,592)	14.745 (12.72, 16.55)	10.494 (9.26, 11.5)	(comparator)	(comparator)	(comparator)	8.759 (7.42, 9.87)	9.333 (8.07, 10.39)
(1) 6 months BPaLM	**BPaLC**	**Yes**	**Every 4 months**	**8,424 (6,469, 10,991)**	**8,167 (6,299, 10,629)**	**14.750 (12.76, 16.54)**	**10.497 (9.28, 11.52)**	**14 (-170, 205) p=0.876**	**0.0032 (-0.16, 0.19) p=0.996**	**4,375**	**8.759 (7.46, 9.90)**	**9.334 (8.09, 10.43)**
(2) 6 months BPaLM	BPaLC	Yes	Every 1 month	8,663 (6,713, 11,219)	8,398 (6,518, 10,767)	14.753 (12.74, 16.49)	10.500 (9.28, 11.50)	--	--	Dominated*	8.713 (7.40, 9.83)	9.304 (8.05, 10.38)
(6) 6 months BPaLM	BPaL only	No	Every 4 months	9,059 (6,926, 11,876)	8,723 (6,707, 11,394)	14.405 (12.44, 16.10)	10.275 (9.07, 11.24)	--	--	Dominated	8.419 (7.10, 9.51)	9.033 (7.78, 10.07)
(3) 6 months BPaLM	BPaL only	Yes	Every 4 months	9,085 (6,935, 11,925)	8,750 (6,703, 11,436)	14.414 (12.42, 16.17)	10.280 (9.10, 11.29)	--	--	Dominated	8.419 (7.07, 9.55)	9.034 (7.80, 10.09)
(4) 6 months BPaLM	BPaL only	Yes	Every 1 month	9,391 (7,201, 12,126)	9,039 (6,950, 11,635)	14.408 (12.42, 16.16)	10.276 (9.08, 11.28)	--	--	Dominated	8.353 (7.04, 9.50)	8.989 (7.71, 10.08)
(7) Standard of care	N/A	Yes	Every 4 months	11,936 (9,403, 15,102)	11,534 (9,088, 14,619)	14.832 (13.00, 16.54)	10.557 (9.46, 11.54)	3,366 (1,465, 5,742) p=<0.001	0.0600 (-0.32, 0.49) p=0.79	56,100	8.103 (6.88, 9.19)	8.915 (7.77, 9.92)
(8) Standard of care	N/A	Yes	Every 1 month	12,232 (9,727, 15,435)	11,816 (9,395, 14,912)	14.836 (12.98, 16.56)	10.560 (9.46, 11.55)	282 (24, 550) p=0.028	0.0025 (-0.16, 0.18) p=0.996	112,800	8.045 (6.83, 9.10)	8.877 (7.73, 9.87)

BPaL – bedaquiline, pretomanid, linezolid; BPaLC – bedaquiline, pretomanid, linezolid, clofazimine; BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin; DST – drug susceptibility testing; Mfx – Moxifloxacin; NHB – Net Health Benefit; QALY – Quality-adjusted Life Year; UI – Uncertainty Interval; USD – United States Dollars; WTP – Willingness-to-Pay.

Strategies listed in order of increasing discounted total cost. Lower bound willingness-to-pay = 4,700 USD/QALY; upper bound willingness-to-pay = 7,021 USD/QALY. Dominated strategies are those that were both more costly and resulted in poorer health than at least one other strategy, based on point estimates. For nondominated strategies (i.e., strategy numbers 1, 5, and 7), the cheapest (Strategy 5) is listed as the comparator. For strategies 1, 7 and 8, incremental discounted total cost and incremental discounted QALYs were calculated relative to the next cheapest, nondominated strategy. The most cost-effective strategy is highlighted in **bold** text. Mean values are shown with accompanying 95% UIs in parentheses.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

*Strategy (2) was dominated by extended dominance; ICER = 77,000 USD/QALY

Fig 1. 6 months of BPaLM is cost-effective in treating RR-TB.

(A) The cost-effectiveness plane shows point estimates for the discounted total costs and discounted QALYs under each modeled strategy. These are calculated as the mean of all simulation runs (1,000 second order Monte Carlo simulations, each with 10,000 individual patient simulations). The efficient frontier (black lines) connects the non-dominated strategies based on point estimates. (B) The cost-effectiveness acceptability curve displays the probability that each modeled strategy is the most cost-effective strategy at different levels of WTP. This probability is calculated as the proportion of 1,000 second-order Monte Carlo simulations where the respective strategy was optimal, given the value for WTP. Strategies were excluded if they were not cost-effective in any of the simulations (these were strategies 3, 4, and 6, where BPaL only was used if Mfx had to be stopped under a BPaLM regimen). Vertical dashed lines mark the lower and upper bounds of the WTP thresholds for Moldova.

*Strategy (2) (6 months BPaLM, BPaLC if Mfx discontinued, DST upfront then every 1 month) was very close to the efficient frontier but was dominated by extended dominance based on point estimates.

BPaL, bedaquiline, pretomanid, linezolid; BPaLC, bedaquiline, pretomanid, linezolid, clofazimine; BPaLM, bedaquiline, pretomanid, linezolid, moxifloxacin; DST, drug susceptibility testing; FQ-R, fluoroquinolone-resistant; FQ-S, fluoroquinolone-susceptible; Mfx, moxifloxacin; QALY, quality-adjusted life year; USD, United States dollars; WTP, willingness-to-pay.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Strategy (5) (6-months BPaLM, second-line DST at 4 months and then every 4 months, BPaLC if Mfx stopped) had the lowest undiscounted lifetime total costs ($8412, 95% UI: [6469, 10991]), followed by Strategy (1) and Strategy (2) (Table 3).

Compared to 6-month BPaLM-based strategies where BPaLC was used if Mfx had to be stopped, strategies continuing only the three-drug regimen BPaL (Strategies (3), (4), and (6)) resulted in worse overall health *and* additional lifetime total costs. The frequency of second-line DST did not lead to large differences in health or cost outcomes (Fig 1).

We compared cost-effectiveness ratios (ICERs) to current cost-effectiveness criteria for Moldova, with the willingness-to-pay for health improvements assumed to fall between $4700 and $7021 per QALY gained. According to this approach Strategy (1) (6-months BPaLM, DST upfront then every 4 months, BPaLC if Mfx stopped) was the most cost-effective strategy with an ICER of $4375 per QALY.

Strategy (7) was potentially cost-effective, but only with a willingness to pay over $56,100 per additional QALY, far higher than the upper bound threshold. In Fig 1B, we show the probability that each strategy is the most cost-effective for given cost-effectiveness thresholds.

Strategies (1), (2), and (5) had the highest probabilities of being cost-effective. All three are 6-month BPaLM strategies where BPaLC was continued for those stopping Mfx, and differ only based on the schedule of routine DST. Taken together, the probability that one of these strategies would be most cost-effective was at least 93% across the range of cost-effectiveness thresholds for Moldova.

For simplicity, we henceforth make comparisons between the leading (i.e., most cost-effective based on point estimates) 6-month BPaLM-based and standard of care-based strategies: Strategy (1) and Strategy (7), respectively. The category-specific costs for these strategies are shown in Fig 2, and the incremental cost-effectiveness for this one-to-one comparison in S7 Fig.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Fig 2. Lifetime costs for 6 months BPaLM and Standard of Care strategies by category.

Undiscounted lifetime costs per individual for Strategy (1) (6 months BPaLM, DST upfront, repeat DST every 4 months, BPaLC if Mfx stopped) as compared to Strategy (7) (standard of care 9-18 month regimens based on results of upfront DST, repeat DST every 4 months). The bars show the mean model outcomes for each cost category, with error bars representing 95% UIs.

BPaLC – bedaquiline, pretomanid, linezolid, clofazimine; BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin; DST – drug susceptibility testing; UI – uncertainty interval; USD – United States Dollars

Compared to the standard of care (Strategy (7)), the incremental NHB of 6 months BPaLM (Strategy (1)) was 0.656 QALYs; (95% UI [-0.091, 1.383] p=0.082) at the lower bound WTP and 0.419 QALYs; (95% UI [-0.206, 0.994] p=0.166) at the upper bound WTP.

Drug resistance

When counting time with resistance across the entire cohort, compared to Strategy (7), Strategy (1) was associated with a non-significant change in the mean duration with any RR-TB of -1.10 months; (95% UI [-4.07, 2.28] p=0.486) (Fig 3, S3 Table). Strategy (1) increased the mean duration with resistance to pretomanid by 0.55 months; (95% UI [0.20, 1.05] p<0.001) and delamanid by 0.54 months; (95% UI [0.18, 1.04] p=0.002) (Fig 3, S3 Table).

Fig 3. Effect of 6 months BPaLM on duration of resistance to key anti-TB drugs.

Results are shown for Strategy (1) (6 months BPaLM, DST upfront, repeat DST every 4 months, BPaLC if Mfx stopped) as compared to Strategy (7) (standard of care 9-18 month regimens based on results of upfront DST, repeat DST every 4 months). For each drug, two estimates are provided: counting time with resistance at any point until the individual is truly cured (dark green), and counting time with resistance only while an individual has TB disease but is not being treated (light green). Both estimates are provided

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

per individual, averaged over the same denominator of the entire cohort initiating treatment. 95% UIs are shown by the accompanying error bars.

BPaLC – bedaquiline, pretomanid, linezolid, clofazimine; BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin; DST – drug susceptibility testing; Mfx, moxifloxacin; SOC – standard of care; TB – Tuberculosis; UI – Uncertainty Interval

In contrast, Strategy (1) decreased the duration with resistance for several drugs: The mean change was -2.21 months for moxifloxacin (95% UI [-3.39, -1.02] p<0.001), -2.28 months for pyrazinamide (95% UI [-4.02, -0.52] p=0.016), -1.31 months for clofazimine (95% UI [-1.94, -0.80] p<0.001), -0.92 months for bedaquiline (95% UI [-1.48, -0.49] p<0.001), -0.95 months for cycloserine (95% UI [-1.38, -0.62] p<0.001), and -0.40 months for amikacin (95% UI [-0.79, -0.06] p=0.022) (Fig 3, S3 Table). When measuring time with resistance only among those with active, untreated RR-TB, or when measuring lifetime cumulative incidence of resistance, the findings revealed a similar picture (Fig 3, S3 Table).

Secondary outcomes

Under Strategy (7), the mean number of grade 4-5 SAEs ever experienced per individual was 0.265 (95% UI: 0.233, 0.300). Strategy (1) resulted in a mean number of grade 4-5 SAEs of 0.237 (95% UI [0.197, 0.284]), conferring a decrease of 0.028 grade 4-5 SAEs per person (95% UI [-0.012, 0.063] p=0.17) over the course of treatment. Fig 4 displays the proportion ever experiencing a grade 4-5 SAE to each drug; the point estimates were lower for Strategy (1) than for Strategy (7) for all drugs except linezolid and pretomanid.

Fig 4. Cumulative incidence of grade 4-5 Severe Adverse Events under 6 months BPaLM and Standard of Care.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

The mean cumulative incidence of Grade 4-5 Severe Adverse Events ever experienced to each of 12 anti-TB drugs is shown for Strategy (1) (6 months BPaLM, DST upfront, repeat DST every 4 months, BPaLC if Mfx stopped) as compared to Strategy (7) (standard of care 9-18 month regimens based on results of upfront DST, repeat DST every 4 months). Estimates are provided per individual, averaged over the entire cohort initiating treatment. The mean estimate is shown by the bar, with 95% UIs represented as error bars. BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin; SAE – grade 4-5 Severe Adverse Event; TB – Tuberculosis; UI – Uncertainty Interval

When health benefits were measured using life years unadjusted for health-related quality of life, strategy (7) again conferred a slightly higher life expectancy than strategy (1) on expectation. Also consistent with the primary QALY-based outcomes, the lowest life expectancy was estimated for Strategies (3), (4), and (6) (BPaLM-based strategies where BPaL was continued in the event of Mfx being stopped). (S4 Table).

For the shorter-term endpoints of 6 months, 12 months, and 17 months (i.e., 72 weeks) from treatment initiation, we found that Strategy (1) resulted in a reduction in the composite unfavorable outcome compared to Strategy (7). The reduction was not significant when using the TB-PRACTECAL aligned definitions for unfavorable outcomes, but was significant and larger in magnitude when using WHO-based definitions (S5 Table, S9 Fig).

Compared to Strategy (7), Strategy (1) would be expected to save Moldova's national TB program budget $7.1 million (95% UI: [1.3 million, 15.4 million] p=0.002) over the five year period from implementation (S6 Table).

Sensitivity Analyses

Fig 5 shows how cost-effectiveness results change for different values of the hazard rate ratio (HRR) of cure, and the initial prevalence of fluoroquinolone resistance, for Strategy (1) as compared to Strategy (7). In these results, Strategy (1) was estimated to be cost-effective (i.e., had a positive Net Health Benefit)

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

compared to Strategy (7) across the range of values used for these parameters. Similarly, total costs were lower for Strategy (1) compared to Strategy (7) across the range of values assessed. Health outcomes were sensitive to the value of the HRR for cure for the BPaLM regimen as compared to standard of care regimens. For low values of the HRR (HRR = 1), Strategy (1) was estimated to lead to a mean 0.90 reduction in QALYs. For high values (HRR = 2), Strategy (1) would lead to a mean 0.35 gain in QALYs. All data files containing these results are available in a repository.[62]

Fig 5. Sensitivity analyses varying relative effectiveness of BPaLM and cohort prevalence of fluoroquinolone resistance.

One-way sensitivity analyses exploring the implications of key model parameters, in terms of their effect on the incremental benefits and costs of Strategy (1) (6 months BPaLM, DST upfront, repeat DST every 4 months, BPaLC if Mfx stopped) as compared to Strategy (7) (standard of care 9-18 month regimens based on results of upfront DST, repeat DST every 4 months). We chose to compare these two strategies as they were the best-performing BPaLM-based and standard of care-based strategies, respectively. In the left column, the HRR of cure for the BPaLM regimen compared to the standard of care is varied. In the right column, we vary the starting prevalence of fluoroquinolone resistance in the cohort (i.e., among all RR-TB). Each of the parameters is varied deterministically in the respective sensitivity analysis, with all other model parameters drawn as in the probabilistic sensitivity analysis. The outcomes quantified on the y-axis for each row of plots are (top to bottom): incremental NHB (calculated using discounted Total Costs and discounted QALYs at the lower bound WTP), incremental QALYs (undiscounted), and incremental Total Costs (undiscounted). The difference between the modeled outcomes under BPaLM and the standard of care is shown for 1,000 model runs, each an average of 10,000 individual patient simulations. The red line shows the trend as represented by regression of the y-axis variable on the x-axis variable, using a generalized additive model with cubic spline to obtain a restricted maximum likelihood within ggplot2.[58] The vertical dashed lines mark the base case assumptions for the mean of each of these model parameters. BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin; FQ – Fluoroquinolone;

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

HRR – Hazard Rate Ratio; NHB – Net Health Benefit QALY – Quality-adjusted Life Year; RR-TB – Rifampicin-resistant tuberculosis

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

DISCUSSION

In this study we assessed the potential health impact and cost effectiveness of a 6-month BPaLM regimen for treating RR-TB in a setting with a high prevalence of drug resistance. Compared to a strategy using 9-18 month regimens based on the 2020 WHO treatment guidelines for drug-resistant TB, we found the 6-month BPaLM regimen would be cost-effective across a range of WTP thresholds, with substantial reductions in the duration and cost of treatment, but little expected change in health outcomes. Though there is considerable overlap between some of the 6-month BPaLM implementation scenarios, there is a clear lead for strategies where clofazimine is used to "top up" the regimen if moxifloxacin must be discontinued because of a grade 4-5 SAE or resistant DST result, compared to continuing on the three-drug BPaL regimen alone. Holding the drug regimen constant, the frequency of second-line DST (to fluoroquinolones and injectables using MGIT) did not result in substantial differences to health or cost outcomes.

Though our analysis was principally concerned with health outcomes over the lifetime horizon, our findings also show that 6 months of BPaLM reduces the risk of unfavorable outcomes over shorter time horizons, in line with the direction of effect observed at 72 weeks in the TB-PRACTECAL randomized controlled trial [8]. On cost-effectiveness specifically, our findings for Moldova are in line with a previous economic evaluation for populations across South Africa, Belarus, and Uzbekistan [28]. Belarus also has a high proportion of RR-TB among individuals newly diagnosed with TB [2], but we do not know whether the joint distribution of resistance to other important drugs would differ between Belarus and Moldova. Although South Africa and Uzbekistan have a lower prevalence of resistance to many drugs, we found that 6 months of BPaLM remained cost-effective when the proportion of RR-TB patients with FQ-R was varied across the wide range of 0-40% (compared to Moldova at 28%). Our analysis builds on the aforementioned cost-effectiveness analysis by explicitly modelling the acquisition of drug resistance, with the initial cohort resistance profile informed by genetic sequencing data from Moldova. We also investigated the potential effects of a larger number of policy implementation scenarios,

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

including the frequency of DST, and whether patients having to stop Mfx under BPaLM should continue on BPaL alone or continue on an alternative four-drug regimen.

When modeling the effectiveness estimate for BPaLM as compared to the standard of care, we assumed that the treatment effect for true cure in the model was approximated by the treatment effect for sputum culture conversion from the TB-PRACTECAL trial [8]. Although the trial measured clinical outcomes, its primary composite outcome measure combined treatment failure, discontinuation, LTFU, death and recurrence, outcomes that are important to distinguish to calculate long-term health outcomes. The numbers of individuals experiencing each of the long-term outcomes of greatest clinical interest were very small. Even if the effect on true cure is not the same as on culture conversion, we found that 6-months BPaLM remained the cost-effective strategy when the HRR (point estimate: 1.59) was varied over a wide range.

While both regimens perform best at lower levels of resistance, sensitivity analyses showed that 6 months of BPaLM may result in a reduction in total QALYs as compared to the standard of care at lower levels of initial FQ-R, or if the BPaLM regimen has lower comparative effectiveness than estimated in the TB-PRACTECAL trial, even while it provides overall value for money. Although policymakers may be uncomfortable adopting interventions that reduce health benefit on expectation, this difference was not statistically significant. Adopting the new regimen would bring substantial benefits in the form of reduced regimen duration, and freeing up funding to spend on other health interventions.

In this analysis we found that 6 months of BPaLM improved or resulted in no change to the duration of disease with resistant strains of *M. tuberculosis* as well as the cumulative incidence of resistance for all anti-TB drugs investigated, except pretomanid and delamanid. Both the duration and cumulative incidence measures were influenced by the starting profile of resistance as informed by the WGS data, the rate of acquisition of new resistance to each drug under each modeled drug regimen, and the monthly rate of cure. Changes in the rate of acquisition of resistance are important for individuals undergoing treatment today (some of the effects of this are captured in the QALYs estimated under each strategy) but

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

preventing new second-line resistance is also important for the health outcomes of those living with RR-TB in the future.

This analysis had several limitations. The Moldovan genomic data used to characterize the resistance profile in the modeled population were from culture positive sputum specimens in 2018-19, and so may not accurately describe current resistance patterns in Moldova or resistance elsewhere, although we hope the sensitivity analysis on the prevalence of FQ-R aids in the generalization of findings. Because the publicly-available WGS dataset excluded samples with mixed strains of *M. tuberculosis* (17.4%), it is possible that our findings do not adequately address this subpopulation with mixed infections, although we note that all the remaining model parameters reflect the real-world health outcomes and costs of a mix of mono- and mixed-strain infections. Furthermore, we assumed that that the true resistance profile was perfectly predicted by the presence or absence of mutations conferring resistance in this data: While the sensitivity and specificity of genomic sequencing is very high for detecting resistance in rifampicin, isoniazid, and ethambutol, the performance is less favorable for moxifloxacin, amikacin, and ethionamide [63].

There are also limitations pertaining to the simulation of health and cost outcomes. The hazard rate ratio for cure was based on the outcome of sputum culture conversion from TB-PRACTECAL; while culture conversion is indeed a prognostic marker in TB [64], it is not a perfect substitute to quantify the rate of true cure, which is unobservable. Further, real-world outcomes with 6-months of BPaLM are likely to be less favorable than in the high-fidelity environment of a randomized controlled trial—for example, there may have been a higher frequency of follow-up in the trial—and the status quo may differ between settings. We did not explicitly model the differences in adherence that may exist between regimens, and we made the simplifying assumption that increasing the number of effective drugs increases the monthly rate of cure and reduces the rate of acquiring resistance. This was based on a previously applied approach [7] and is likely to hold qualitatively, but we did not account for the all the differences that may exist between specific drugs, and the interactions between them. For example, the effectiveness of BPaLC vs. BPaL may not be the same as the effectiveness of BPaLM vs. BPaL, yet—SAEs aside—the modeling

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

approach was agnostic to this, conditional on the number of "effective" drugs in the regimen. For parsimony, we did not explicitly model changes in smear status. For individuals no longer receiving treatment, we adopted a mortality rate estimate for smear-positive TB, which may overestimate mortality specifically for those who appear to have completed treatment successfully but not truly cured; this would likely bias the results against shorter, 6-month BPaLM strategies. While the relationship between HIV and RR-TB treatment outcomes is neither straight-forward nor consistent [38,65], we did not model HIV status at the individual level and as such we were unable to comment specifically on health outcomes for those with TB-HIV coinfection. Although the probability of a grade 4-5 SAE was modelled separately for each drug, we did not incorporate variation in the duration and consequences of each type of SAE. Finally, we did not account for the secondary effects resulting from onward transmission of RR-TB, and our results may therefore not capture the full cost-effectiveness implications of each modelled strategy. To account for this explicitly, it would be necessary to model the transmission dynamics of *M. tuberculosis*. Instead, we estimated the cumulative incidence and duration of resistance as surrogates for the long-term health outcomes they may affect, insofar as lower incidence and fewer months of resistant disease might each result in less transmission of resistant strains.

This study was conducted in the setting of Moldova, a country with a high proportion of RR-TB with resistance to second-line drugs. By conducting sensitivity analysis on the proportion with FQ-R, we aimed to aid the generalization of findings to other settings. Many of the health-related model parameters are also generalizable beyond Moldova: TB outcomes under the standard of care were informed by multi-national meta-analyses, and the estimate for comparative effectiveness was from a multi-national trial (S1 Table). However, many of the cost parameters were from Moldova and Georgia (GDP per capita of $5,563 and $6,628 in 2022, respectively) [66], and so there are likely limitations in the generalization of incremental costs of 6 months BPaLM compared to the standard of care, especially to countries with very different income levels.

To optimize clinical care for RR-TB, decision makers must take account of important health and economic effects for affected individuals as well as society at large. In this study, we estimated favorable

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

cost-effectiveness for the 6-month BPaLM regimen in settings with a high burden of drug resistance, conditional on BPaLC being used in the event of moxifloxacin being contraindicated, rather than BPaL alone. The schedule of second-line DST did not appear to affect health outcomes or costs to a great degree across the finite number of DST schedules we explored, and further analyses may be warranted to explore the optimal testing frequency in Moldova and other settings—especially where second-line DST capacity is limited or unavailable [67]—and to explore additional technologies beyond MGIT for identifying resistance to fluoroquinolones and injectables. The forthcoming results of the endTB trial [9–13] will expand the evidence base for shorter regimens, and while the trial investigated 9- as opposed to the 6-month regimens investigated in this study, this still represents a substantial shortening compared to many standard of care regimens. The growing body of both empirical and modeling literature may also highlight the elements of treating RR-TB—including the choice of drugs, duration of regimen, and frequency and modality of DST—which overall provide the best treatment strategy, for each patient's specific needs. Clinical and health policy decisions alike would be enhanced by continued collective efforts to strengthen the evidence base in the ways most likely to optimize care, with sufficient numbers of patients to quantify long-term health outcomes across multiple settings.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Acknowledgments

For helpful feedback on research-in-progress presentations, LPJ would like to thank current and former students, postdocs and faculty affiliated with: the Center for Health Decision Science, the PhD Program in Health Policy, and the Center for AIDS Research, all at Harvard University, Cambridge, MA, USA; the Decision Science Methods Group at Erasmus University, Rotterdam, the Netherlands.

Author Contributions

Conceptualization:	LPJ, NAM, TC, JF, SS, RY, VC, NC, AC
Data curation:	LPJ, TC, NAM
Formal Analysis:	LPJ, NAM
Funding Acquisition:	LPJ, NAM, TC
Investigation:	LPJ, NAM, TC, MFF
Methodology:	LPJ, NAM, SS, RY
Project Administration:	LPJ, NAM
Resources:	LPJ, NAM
Software:	LPJ, NAM, FK
Supervision:	NAM, TC
Validation:	LPJ, TC, MFF, NAM, DC, JF, VC
Visualization:	LPJ, FK, NAM
Writing – Original Draft:	LPJ, NAM
Writing – Review & Editing:	LPJ, NAM, MFF, TC, JF, FK, SS, RY, DC, NC, VC, AC

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Abbreviations

BPaL, bedaquiline, pretomanid, linezolid; BPaLC, bedaquiline, pretomanid, linezolid, clofazimine; BPaLM, bedaquiline, pretomanid, linezolid, moxifloxacin; CDF – cumulative distribution function; CI – confidence interval; CrI – credibility interval; CPI – Consumer Price Index; DST – drug susceptibility testing; FQ-R, fluoroquinolone-resistant; FQ-S, fluoroquinolone-susceptible; LJ – Lowenstein-Jensen; MDL – Moldovan Leu; GDP – Gross Domestic Product; GEL – Georgian Lei; HIV – human immunodeficiency virus; LTFU – lost to follow up; LY – Life Year; *M. tb.* – *Mycobacterium tuberculosis*; MDR-TB – multidrug-resistant tuberculosis; NHB – Net Health Benefit; QALY – Quality-adjusted Life Year; RR-TB – rifampicin-resistant tuberculosis; SAE – grade 4-5 Severe Adverse Event; SEM – Standard Error of the Mean; SMR – standardized mortality ratio; TB – tuberculosis; UI – Uncertainty Interval; USD – United States Dollars; WTP – Willingness-to-Pay; XDR-TB – extensively drug-resistant tuberculosis.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

REFERENCES

1. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. [date accessed: 29 Mar 2023]. Available: https://www.who.int/publications/i/item/9789240063129

2. WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. World Health Organization; 2020. Available: https://www.who.int/publications-detail-redirect/9789240007048

3. Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A, Brode S, et al. Standardised shorter regimens *versus* individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J. 2020;55: 1901467. doi:10.1183/13993003.01467-2019

4. Kempker RR, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, Bablishvili N, et al. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens. Clin Infect Dis Off Publ Infect Dis Soc Am. 2019;71: 2336–2344. doi:10.1093/cid/ciz1107

5. Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022;387: 810–823. doi:10.1056/NEJMoa2119430

6. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis. N Engl J Med. 2020;382: 893–902. doi:10.1056/NEJMoa1901814

7. Kendall EA, Malhotra S, Cook-Scalise S, Denkinger CM, Dowdy DW. Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations. BMC Infect Dis. 2019;19. doi:10.1186/s12879-019-4429-x

8. Nyang'wa B-T, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022;387: 2331–2343. doi:10.1056/NEJMoa2117166

9. endTB clinical trial results | endTB. [date accessed: 21 Nov 2023]. Available: https://endtb.org/endtb-clinical-trial-results

10. Mitnick CD. endTB trial: Design and baseline characteristics of participants in a study of five all-oral, shortened regimens for MDR/RR-TB. TBUnion; 2023 Nov 15; Paris. Available: https://documents.theunion.org/web-uploads/UNION2023_Abstracts_High.pdf?_gl=1*1kgeq4f*_ga_8PZRTR8JPW*MTcwNTkzOTczMC4xLjAuMTcwNTkzOTczNC4wLjAuMA..

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

11. Khan U. endTB trial: Efficacy results in a study of five all-oral, shortened regimens for MDR/RR-TB. TBUnion; 2023 Nov 15; Paris. Available: https://documents.theunion.org/web-uploads/UNION2023_Abstracts_High.pdf?_gl=1*1kgeq4f*_ga_8PZRTR8JPW*MTcwNTkzOTczMC4xLjAuMTcwNTkzOTczNC4wLjAuMA..

12. Guglielmetti L. endTB trial: Safety results in a study of five shortened, all-oral regimens for MDR/RR-TB. TBUnion; 2023 Nov 15; Paris. Available: https://documents.theunion.org/web-uploads/UNION2023_Abstracts_High.pdf?_gl=1*1kgeq4f*_ga_8PZRTR8JPW*MTcwNTkzOTczMC4xLjAuMTcwNTkzOTczNC4wLjAuMA..

13. Velásquez G. endTB trial sub-studies: Evidence on resistance and pharmacokinetics/ pharmacodynamics to inform practice. TBUnion; 2023 Nov 15; Paris. Available: https://documents.theunion.org/web-uploads/UNION2023_Abstracts_High.pdf?_gl=1*1kgeq4f*_ga_8PZRTR8JPW*MTcwNTkzOTczMC4xLjAuMTcwNTkzOTczNC4wLjAuMA..

14. Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020;8: 383–394. doi:10.1016/S2213-2600(20)30047-3

15. Thomas BE, Shanmugam P, Malaisamy M, Ovung S, Suresh C, Subbaraman R, et al. Psycho-Socio-Economic Issues Challenging Multidrug Resistant Tuberculosis Patients: A Systematic Review. PLOS ONE. 2016;11: e0147397. doi:10.1371/journal.pone.0147397

16. Isaakidis P, Rangan S, Pradhan A, Ladomirska J, Reid T, Kielmann K. “I cry every day”: experiences of patients co-infected with HIV and multidrug-resistant tuberculosis. Trop Med Int Health TM IH. 2013;18: 1128–1133. doi:10.1111/tmi.12146

17. Morris MD, Quezada L, Bhat P, Moser K, Smith J, Perez H, et al. Social, economic, and psychological impacts of MDR-TB treatment in Tijuana, Mexico: a patient’s perspective. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2013;17: 954–960. doi:10.5588/ijtld.12.0480

18. Mauch V, Melgen R, Marcelino B, Acosta I, Klinkenberg E, Suarez P. Tuberculosis patients in the Dominican Republic face severe direct and indirect costs and need social protection. Rev Panam Salud Publica Pan Am J Public Health. 2013;33: 332–339. doi:10.1590/s1020-49892013000500004

19. Kendall EA, Theron D, Franke MF, van Helden P, Victor TC, Murray MB, et al. Alcohol, hospital discharge, and socioeconomic risk factors for default from multidrug resistant tuberculosis treatment in rural South Africa: a retrospective cohort study. PloS One. 2013;8: e83480. doi:10.1371/journal.pone.0083480

20. Global Drug Facility (GDF) Medicines Catalog. Stop TB Partnership; 2022. Available: https://www.stoptb.org/sites/default/files/gdfmedicinescatalog_1.pdf

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

21. Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment. In: TB Alliance [Internet]. [date accessed: 17 Jun 2023]. Available: https://www.tballiance.org.za/news/price-reduction-paves-the-way-for-expanded-access-to-highly-effective-multidrug-resistant-tuberculosis-treatment

22. Kaniga K, Hasan R, Jou R, Vasiliauskienė E, Chuchottaworn C, Ismail N, et al. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates. J Clin Microbiol. 2022;60: e02919-20. doi:10.1128/JCM.02919-20

23. Dheda K, Gumbo T, Lange C, Horsburgh CR, Furin J. Pan-tuberculosis regimens: an argument against. Lancet Respir Med. 2018;6: 240–242. doi:10.1016/S2213-2600(18)30097-3

24. zur Wiesch PA, Kouyos R, Engelstädter J, Regoes RR, Bonhoeffer S. Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect Dis. 2011;11: 236–247. doi:10.1016/S1473-3099(10)70264-4

25. Vanino E, Granozzi B, Akkerman OW, Munoz-Torrico M, Palmieri F, Seaworth B, et al. Update of drug-resistant tuberculosis treatment guidelines: A turning point. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2023; S1201-9712(23)00089–9. doi:10.1016/j.ijid.2023.03.013

26. Practical manual on tuberculosis laboratory strengthening, 2022 update. [date accessed: 21 Nov 2023]. Available: https://www.who.int/publications-detail-redirect/9789240061507

27. Pai M, Palamountain KM. New tuberculosis technologies: challenges for retooling and scale-up [State of the art series. New tools. Number 4 in the series]. Int J Tuberc Lung Dis. 2012;16: 1281–1290. doi:10.5588/ijtld.12.0391

28. Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, Dodd M, et al. Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis. PLOS Glob Public Health. 2022;2: e0001337. doi:10.1371/journal.pgph.0001337

29. Global tuberculosis report 2020. [date accessed: 4 Apr 2023]. Available: https://www.who.int/publications/i/item/9789240013131

30. Yang C, Sobkowiak B, Naidu V, Codreanu A, Ciobanu N, Gunasekera KS, et al. Phylogeography and transmission of M. tuberculosis in Moldova. 2021 Jul p. 2021.06.30.21259748. doi:10.1101/2021.06.30.21259748

31. Download: The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective: Summary of a Joint Workshop by the Institute of Medicine and the Russian Academy of Medical Science | The National Academies Press. [date accessed: 21 Nov 2023]. Available: https://nap.nationalacademies.org/download/13033

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

32. Stuckler D, Basu S, McKee M, King L. Mass incarceration can explain population increases in TB and multidrug-resistant TB in European and central Asian countries. Proc Natl Acad Sci. 2008;105: 13280–13285. doi:10.1073/pnas.0801200105

33. Yang C, Sobkowiak B, Naidu V, Codreanu A, Ciobanu N, Gunasekera KS, et al. Phylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis. PLOS Med. 2022;19: e1003933. doi:10.1371/journal.pmed.1003933

34. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. [date accessed: 2 Mar 2023]. Available: https://www.who.int/publications-detail-redirect/9789240063129

35. ID 736718 - BioProject - NCBI. [date accessed: 9 Feb 2023]. Available: https://www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/bioproject/PRJNA736718

36. Ragonnet R, Flegg JA, Brilleman SL, Tiemersma EW, Melsew YA, McBryde ES, et al. Revisiting the Natural History of Pulmonary Tuberculosis: A Bayesian Estimation of Natural Recovery and Mortality Rates. : 9.

37. Romanowski K, Baumann B, Basham CA, Ahmad Khan F, Fox GJ, Johnston JC. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19: 1129–1137. doi:10.1016/S1473-3099(19)30309-3

38. Bastos ML, Lan Z, Menzies D. An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis. Eur Respir J. 2017;49. doi:10.1183/13993003.00803-2016

39. Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Walt MVD, Kvasnovsky C, et al. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study. PLOS Med. 2015;12: e1001932. doi:10.1371/journal.pmed.1001932

40. Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis. Ann Intern Med. 2008;149: 123–134. doi:10.7326/0003-4819-149-2-200807150-00008

41. Hunink MGM. Decision making in health and medicine:integrating evidence and values. Second edition. Cambridge: University Press; 2014.

42. Weinstein MC, Stason WB. Foundations of Cost-Effectiveness Analysis for Health and Medical Practices. N Engl J Med. 1977;296: 716–721. doi:10.1056/NEJM197703312961304

43. Feeny D, Krahn M, Prosser L, Salomon JA. Valuing Health Outcomes. 2nd ed. Cost-effectiveness in Health and Medicine. 2nd ed. Oxford University Press; 2016. pp. 167–200. Available: https://hollis.harvard.edu/primo-explore/fulldisplay?docid=TN_cdi_proquest_ebookcentralchapters_4740819_18_202&cont

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

ext=PC&vid=HVD2&lang=en_US&search_scope=everything&adaptor=primo_central_multiple_fe&tab=everything&query=any,contains,neumann%20cost-effectiveness

44. Weinstein MC, Torrance G, McGuire A. QALYs: The Basics. Value Health. 2009;12: S5–S9. doi:10.1111/j.1524-4733.2009.00515.x

45. Portnoy A, Yamanaka T, Nguhiu P, Nishikiori N, Garcia Baena I, Floyd K, et al. Costs incurred by people receiving tuberculosis treatment in low-income and middle-income countries: a meta-regression analysis. Lancet Glob Health. 2023;11: e1640–e1647. doi:10.1016/S2214-109X(23)00369-8

46. Meltzer DO, Basu A, Sculpher MJ. Theoretical Foundations of Cost-Effectiveness Analysis in Health and Medicine. In: Neumann PJ, Ganiats TG, Russell LB, Sanders GD, Siegel JE, editors. Cost-Effectiveness in Health and Medicine. Oxford University Press; 2016. p. 0. doi:10.1093/acprof:oso/9780190492939.003.0002

47. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Glob Health. 2018;3: e000964. doi:10.1136/bmjgh-2018-000964

48. Paulden M. Why it's Time to Abandon the ICER. PharmacoEconomics. 2020;38: 781–784. doi:10.1007/s40273-020-00915-5

49. Husereau D, Drummond M, Augustovski F, De Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25: 10–31. doi:10.1016/j.jval.2021.10.008

50. Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2012;15: 835–842. doi:10.1016/j.jval.2012.04.014

51. TreeAge Pro Healthcare 2023. TreeAge Software, Williamstown, MA; Available: http://www.treeage.com

52. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.; 2022. Available: https://www.R-project.org/

53. Warnes GR, Bolker B, Gorjanc G, Grothendieck G, Korosec A, Lumley T, et al. gdata: Various R Programming Tools for Data Manipulation. 2022. Available: https://cran.r-project.org/web/packages/gdata/index.html

54. Wickham H, RStudio. tidyverse: Easily Install and Load the "Tidyverse." 2023. Available: https://cran.r-project.org/web/packages/tidyverse/index.html

55. Wickham H, RStudio. stringr: Simple, Consistent Wrappers for Common String Operations. 2022. Available: https://cran.r-project.org/web/packages/stringr/index.html

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

56. Robinson D, Hayes A, Couch [aut S, cre, Software P, PBC, et al. broom: Convert Statistical Objects into Tidy Tibbles. 2023. Available: https://cran.r-project.org/web/packages/broom/index.html

57. Wickham H, François R, Henry L, Müller K, Vaughan D, Software P, et al. dplyr: A Grammar of Data Manipulation. 2023. Available: https://cran.r-project.org/web/packages/dplyr/index.html

58. Kassambara A. ggpubr: "ggplot2" Based Publication Ready Plots. 2023. Available: https://cran.r-project.org/web/packages/ggpubr/index.html

59. Garnier S, Ross N, Rudis B, Sciaini M, Camargo AP, Scherer C. viridis: Colorblind-Friendly Color Maps for R. 2021. Available: https://cran.r-project.org/web/packages/viridis/index.html

60. Firke S, Denney B, Haid C, Knight R, Grosser M, Zadra J. janitor: Simple Tools for Examining and Cleaning Dirty Data. 2023. Available: https://cran.r-project.org/web/packages/janitor/index.html

61. Wickham H. reshape2: Flexibly Reshape Data: A Reboot of the Reshape Package. 2020. Available: https://cran.r-project.org/web/packages/reshape2/index.html

62. James LP. lyndonpjames/BPaLM_Moldova. [date accessed: 22 Jan 2024]. Available: https://github.com/lyndonpjames/BPaLM_Moldova/tree/main

63. The CRyPTIC Consortium. A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics. Ladner J, editor. PLOS Biol. 2022;20: e3001721. doi:10.1371/journal.pbio.3001721

64. Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med. 2015;3: 201–209. doi:10.1016/S2213-2600(15)00036-3

65. Sergeev R, Colijn C, Murray M, Cohen T. Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis. Sci Transl Med. 2012;4: 135ra67. doi:10.1126/scitranslmed.3003815

66. World Bank Open Data. Available: https://data.worldbank.org/

67. Wallis RS, Cohen T, Menzies NA, Churchyard G. Pan-tuberculosis regimens: an argument for. Lancet Respir Med. 2018;6: 239–240. doi:10.1016/S2213-2600(18)30096-1

68. Global Tuberculosis Programme. Tuberculosis Data. 2023. Available: https://www.who.int/teams/global-tuberculosis-programme/data

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

69. Tasneen R, Williams K, Amoabeng O, Minkowski A, Mdluli KE, Upton AM, et al. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrob Agents Chemother. 2015;59: 129–135. doi:10.1128/AAC.03822-14

70. Liu Y, Gao J, Du J, Shu W, Wang L, Wang Y, et al. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021;102: 392–396. doi:10.1016/j.ijid.2020.10.081

71. Nambiar R, Tornheim JA, Diricks M, Bruyne KD, Sadani M, Shetty A, et al. Linezolid resistance in Mycobacterium tuberculosis isolates at a tertiary care centre in Mumbai, India. Indian J Med Res. 2021;154: 85–89. doi:10.4103/ijmr.IJMR_1168_19

72. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367: 1508–1518. doi:10.1056/NEJMoa1201964

73. Kohli-Lynch CN. Probabilistic sensitivity analysis and value of information analysis. 1st ed. In: Bishai D, Brenzel L, Padula W, editors. Handbook of Applied Health Economics in Vaccines. 1st ed. Oxford University PressOxford; 2023. pp. 290–309. doi:10.1093/oso/9780192896087.003.0024

74. Blöndal K, Viiklepp P, Guðmundsson LJ, Altraja A. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012;16: 1228–1233. doi:10.5588/ijtld.12.0037

75. World Population Prospects. UN Population Division, Department of Economic and Social Affairs.; 2019. Available: https://population.un.org/wpp/Download/Files/1_Indicators%20(Standard)/EXCEL_FILES/3_Mortality/WPP2019_MORT_F15_1_LIFE_TABLE_SURVIVORS_BOTH_SEXES.xlsx

76. Walker IF, Shi O, Hicks JP, Elsey H, Wei X, Menzies D, et al. Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients. Eur Respir J. 2019;54. doi:10.1183/13993003.00353-2018

77. A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India. Bull World Health Organ. 1960;23: 535–585.

78. Gils T, Lynen L, de Jong BC, Van Deun A, Decroo T. Pretomanid for tuberculosis: a systematic review. Clin Microbiol Infect. 2022;28: 31–42. doi:10.1016/j.cmi.2021.08.007

79. Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J. 2019;54. doi:10.1183/13993003.01522-2019

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

80. Schnippel K, Firnhaber C, Berhanu R, Page-Shipp L, Sinanovic E. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa. Int J Tuberc Lung Dis. 2018;22: 393–398. doi:10.5588/ijtld.17.0661

81. Bauer M, Ahmed S, Benedetti A, Greenaway C, Lalli M, Leavens A, et al. The impact of tuberculosis on health utility: a longitudinal cohort study. Qual Life Res. 2015;24: 1337–1349. doi:10.1007/s11136-014-0858-6

82. Takahara M, Katakami N, Shiraiwa T, Abe K, Ayame H, Ishimaru Y, et al. Evaluation of health utility values for diabetic complications, treatment regimens, glycemic control and other subjective symptoms in diabetic patients using the EQ-5D-5L. Acta Diabetol. 2019;56: 309–319. doi:10.1007/s00592-018-1244-6

83. Chikovani I, Shengelia N, Marjanishvili N, Gabunia T, Khonelidze I, Cunnama L, et al. Cost of TB services in the public and private sectors in Georgia (No 2). Int J Tuberc Lung Dis. 2021;25: 1019–1027. doi:10.5588/ijtld.21.0176

84. Cates L, Crudu V, Codreanu A, Ciobanu N, Fosburgh H, Cohen T, et al. Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2021;25: 228–230. doi:10.5588/ijtld.20.0586

85. Myambutol (ethambutol) dosing, indications, interactions, adverse effects, and more. [date accessed: 18 Feb 2023]. Available: https://reference.medscape.com/drug/myambutol-ethambutol-342677

86. pyrazinamide: Dosing, contraindications, side effects, and pill pictures - epocrates online. [date accessed: 18 Feb 2023]. Available: https://online.epocrates.com/drugs/279/pyrazinamide

87. Sweeney S, Cunnama L, Laurence Y, Garcia Baena I, Kairu A, Minyewelet M, et al. Value TB Dataset: costs per intervention. Harvard Dataverse; 2021. doi:10.7910/DVN/QOI6IR

88. UNdata | record view | Life expectancy at birth for both sexes combined (years). [date accessed: 24 Mar 2022]. Available: http://data.un.org/Data.aspx?q=moldova&d=PopDiv&f=variableID%3A68%3BcrID%3A498

89. xe.com Currency Charts. Available: https://www.xe.com/currencycharts/

90. World Bank International Comparisons Project. [date accessed: 21 Mar 2022]. Available: https://databank.worldbank.org/embed/ICP-2017-Cycle/id/4add74e?inf=n

91. Tekin K, Albay A, Simsek H, Sig AK, Guney M. Evaluation of the BACTEC MGIT 960 SL DST Kit and the GenoType MTBDRsl Test for Detecting Extensively Drug-resistant Tuberculosis Cases. Eurasian J Med. 2017;49: 183–187. doi:10.5152/eurasianjmed.2017.17040

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

92. Devasia RA, Blackman A, May C, Eden S, Smith T, Hooper N, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother. 2009;63: 1173–1178. doi:10.1093/jac/dkp096

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

S1 Checklist. CHEERS 2022 Checklist.

S1 Appendix. Additional Detail on Microsimulation Model.

Here we provide an enhanced level of detail on some of the model structure. Specific elements reference sources from the literature [2,41,48,68–73].

S2 Appendix. Additional Detail on Calculated Model Parameters.

Here we provide notation for how specific model parameters were derived from published sources [38,74].

S1 Table. Model input parameters, complete set.

CDF – cumulative distribution function; CI – confidence interval; CrI – credibility interval; CPI – Consumer Price Index; DST – drug susceptibility testing; LJ – Lowenstein-Jensen; MDL – Moldovan Leu; GDP – Gross Domestic Product; GEL – Georgian Lei; LTFU – lost to follow up; M. tb. – mycobacterium tuberculosis; NHB – Net Health Benefit; QALY – Quality-adjusted Life Year; SAE – Severe Adverse Event; SEM – Standard Error of the Mean; SMR – standardized mortality ratio; UI – Uncertainty Interval; USD – United States Dollars; WTP – Willingness-to-Pay.

*denotes a parameter where there was no readily available measure of dispersion. For these parameters, we assumed a standard deviation equal to one third of the mean.

Parameter details are accompanied by citations from the literature [8,14,20,36–40,45,47,66,68,74–92].

S2 Table. Probability of loss to follow up by month of treatment.

LTFU – Lost to Follow Up.

LTFU data from Walker et al. 2019 [76]. *The values in the rightmost column are used as the model inputs. Compared to the fourth column, we rounded down the values from month 21 onwards such that the probability of LTFU is zero thenceforth.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

S3 Table. Duration and cumulative incidence of resistance to key drugs.

BPaLM, bedaquiline, pretomanid, linezolid, moxifloxacin; SOC, standard of care.

The entire cohort had RR-TB, and so the duration with rifampicin resistance is equivalent to the duration with active RR-TB, and the cumulative incidence of rifampicin resistance is not applicable. Some drugs were used very sparingly, if ever, under one or both strategies (e.g., amikacin, ethambutol, ethionamide, isoniazid, and pyrazinamide); as such the cumulative incidence may be very low for these drugs under one or both strategies.

S4 Table. Life Years achieved under each RR-TB treatment strategy.

BPaL – bedaquiline, pretomanid, linezolid; BPaLC – bedaquiline, pretomanid, linezolid, clofazimine; BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin; UI – Uncertainty Interval.

Strategies are listed in the same order as Table 3. Mean values are shown with accompanying 95% UIs in parentheses.

S5 Table. Comparing outcomes at 6 months, 12 months, and 72 weeks from treatment initiation.

BPaLC – bedaquiline, pretomanid, linezolid, clofazimine; BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin; LYs – Life Years; Mfx – moxifloxacin; p.p. – percentage points; QALYs – Quality-adjusted Life Years; UI – Uncertainty Interval; WHO – World Health Organization

The following health outcomes are shown: a composite "Unfavorable outcome" closely aligned to the composite trial endpoint in TB-PRACTECAL, true cure, and quality-adjusted life expectancy. Results are shown separately over three model-run time horizons: 6 months, 72 weeks (in line with the endpoint in TB-PRACTECAL), and lifetime (in line with the primary outcomes in our analysis).

S6 Table. Five-year budget impact of implementing 6 months of BPaLM in Moldova.

TB – tuberculosis.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

The budget impact was estimated for 6 months BPaLM (Strategy (1)) as compared to standard of care (Strategy (7))

S1 Fig. Schematic of the initial workup phase for the standard of care

Both standard of care strategies (Strategy 7 and Strategy 8) are modeled on the recommended workup and regimen selection in the 2020 WHO guidelines on the treatment of drug-resistant tuberculosis [2]. We assumed that DST results (by MGIT) are available in 2 weeks. *While we include the BPaL regimen as per the guidelines, no patients actually met the criteria to receive it under the standard of care (Strategies 7 and 8) in our model (i.e., in all model simulations, it is possible to adopt a WHO longer regimen). BPaL – bedaquiline, pretomanid, linezolid; DST – drug susceptibility test; FQ – fluoroquinolone; MGIT – Mycobacterial Growth Indicator Tube; WHO – World Health Organization

S2 Fig. ***M. tb*. genomic sequencing data exclusion criteria.**

*The full dataset did not include any samples with mixed strains of *M. tb*.

Exclusions made to the genomic sequencing drug susceptibility testing dataset are shown along with the number of observations. This dataset is described elsewhere [30,35]. The presence of a mutation conferring resistance to rifampicin was assumed to convey full resistance, and vice versa.

TB – tuberculosis.

S3 Fig. The rate of acquiring drug resistance.

The modeled point estimate for the monthly rate that an individual's strain of *M. tuberculosis* will acquire resistance to each effective drug it is exposed to is plotted, conditional on that individual beginning the

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

month with *n* effective drugs in the regimen (x-axis). Estimates for 1, 3 and 4 effective drugs were obtained from the literature. The estimate for 2 drugs was calculated, assuming an additive risk (i.e., the increase in risk for 2 effective drugs compared to 3 is the same as the increase in risk for 3 effective drugs compared to 4). See also S1 Table.

S4 Fig. Markov state-transition diagram.

Transitions between states can occur as shown by the arrows. Though not receiving treatment, individuals in the "Active TB, no longer receiving treatment" state are subject to a low rate of self-cure, and so may still transition to the "Cured post-treatment" state. Asterisks (*) highlight the major mechanisms through which the choice of treatment intervention affects outcomes. LTFU – Lost to follow-up; TB – tuberculosis.

S5 Fig. Cohort prevalence of *M. tb.* resistance to key drugs at treatment initiation.

The proportion of the cohort with primary resistance to each drug is plotted, as described by *M. tuberculosis* whole genomic sequencing data from Moldova [30,35]. All those observations with rifampicin susceptibility were excluded, as per S3 Fig. *There was no resistance data for pretomanid; resistance was assumed to be at the same level as for delamanid.

S6 Fig. WHO-based definitions for End of Treatment Outcomes.

Schematic showing the definitions for end of treatment outcomes used by the WHO (A), and this model (B). The constituents of each of the major end of treatment outcome categories are shown, as applied to all RR-TB including MDR-TB and XDR-TB. Differences between the WHO definitions and those used in this model are highlighted by the gray hashed boxes. The WHO definitions are not necessarily mutually exclusive; we assumed that the classification takes place according to the tree structure in (A),

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

and implemented the aligned structure in (B) for tractability given the model mechanisms. For example, an individual who failed treatment and then died would be recorded as a death, because the branch involving death is closer to the root of the tree.

S7 Fig. Incremental cost-effectiveness plane for the leading 6-month BPaLM strategy vs. the leading SOC strategy.

The incremental cost-effectiveness plane compares the incremental discounted total QALYs and incremental discounted total costs for Strategy (1) as compared to a reference of Strategy (7). Each light pink point represents one iteration of the second-order Monte Carlo simulation, itself an average of 10,000 individual patient simulations. The purple diamond is the mean of the 1,000 second-order Monte Carlo simulations, corresponding to the point estimates in Table 3. The blue dot represents the standard of care (Strategy (7)), which is the reference point. BPaL – bedaquiline, pretomanid, linezolid; BPaLC – bedaquiline, pretomanid, linezolid, clofazimine; BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin; FQ-R – fluoroquinolone-resistant; FQ-S – fluoroquinolone-susceptible; Mfx – moxifloxacin; QALY – quality-adjusted life year; USD – United States dollars; WTP – willingness-to-pay

S8 Fig. Sensitivity analyses varying relative effectiveness of BPaLM and cohort prevalence of fluoroquinolone resistance, outcome of Life Years.

One-way sensitivity analyses testing the effect of key model parameter assumptions, in terms of their effect on the incremental Life Years experienced under the Strategy (1) (6 months BPaLM, DST upfront, repeat DST every 4 months, BPaLC if Mfx stopped) as compared to Strategy (7) (standard of care 9-18 month regimens based on results of upfront DST, repeat DST every 4 months). We chose to compare these two strategies as they were the best-performing BPaLM-based and standard of care-based strategies, respectively. Each of the parameters is varied deterministically in the respective sensitivity analysis, with all other model parameters drawn as in the probabilistic sensitivity analysis. In the left column, the HRR

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293104; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

of cure for the BPaLM regimen compared to the standard of care is varied. In the right column, we vary the starting prevalence of fluoroquinolone resistance in the cohort. Each of 1,000 model runs is shown in each plot, itself an average of 10,000 individual patient simulations. The red line shows the trend as represented by regression of the y-axis variable on the x-axis variable, using a generalized additive model with cubic spline to obtain a restricted maximum likelihood within ggplot2 [58]. The vertical dashed lines mark the base case assumption for the mean of each of these model parameters. FQR – Fluoroquinolone Resistance; HRR – Hazard Rate Ratio; LY –Life Year; RR-TB – Rifampicin-resistant tuberculosis

S9 Fig. Validating modeled End of Treatment outcomes against data reported to WHO.

The proportions recorded for each EOT outcome are shown for WHO RR-TB data 2010–2019 for Moldova (left of the vertical dashed line) and the modeled cohort outcomes (right of the vertical dashed line), where we assume that all EOT outcome categories are mutually exclusive, and that death during treatment or LTFU take precedence over a preceding treatment failure. Standard of care refers to modelled Strategy 7, and 6 months BPaLM refers to modelled Strategy 1. The number of observations per year in the WHO TB outcomes data for all MDR/RR-TB is in the range (559, 996).

BPaLM – bedaquiline, pretomanid, linezolid, moxifloxacin; EOT – End Of Treatment; LTFU – Lost to Follow Up; RR-TB – Rifampicin-resistant tuberculosis; WHO – World Health Organization


A
Total Discounted Cost (2022 USD)
12000
11000
10000
9000
8000
Strategy (8):
9-18 month regimens
DST upfront
Repeat DST every 1 month
Strategy (7):
9-18 month regimens
DST upfront
Repeat DST every 4 months
Strategy (1):
6 months BPaLM
DST upfront
Repeat DST every 4 months
BPaLC if Mfx stopped
Strategy (5):
6 months BPaLM
No DST upfront, start at month 4
Repeat DST every 4 months
BPaLC if Mfx stopped
10.2
10.4
10.6
10.8
Total Discounted QALYs
B
Probability of being cost-effective
0.6
0.4
0.2
0.0
Lower bound WTP
for Moldova
Upper bound WTP
for Moldova
0
5000
10000
15000
Willingness to pay (2022 USD/QALY)
Standard of Care:
9 month regimen if FQ-S
18 month regimen if FQ-R
6 months BPaLM
Schedule of DST to 2nd line drugs
For 6 months BPaLM only:
If Mfx stopped, continue with
BPaLC
BPaL only
Start month 1, then every 4 months
Start month 1, then every month
Start month 4, then every 4 months


Base case
HRR = 1.59
Base case
prevalence
= 0.28
Incremental NHB (QALYs)
Incremental QALYs
Incremental Total Cost (2022 USD)
HRR of cure for BPaLM compared to the SOC
Prevalence of FQ resistance among RR-TB


Lifetime cumulative incidence of Grade 4-5 SAEs
(per patient)
0.25
0.20
0.15
0.10
0.05
0.00
Amikacin
Bedaquiline
Clofazimine
Cycloserine
Delamanid
Ethambutol
Ethionamide
Isoniazid
Linezolid
Moxifloxacin
Pretomanid
Pyrazinamide
Drug
Strategy
(1): 6 months BPaLM
(7): Standard of Care


Difference in the mean duration with TB disease resistant to each drug (months)
2
0
-2
-4
-6
Counting time with resistance among:
Entire cohort
Only those with higher transmission risk (i.e., active TB no longer receiving treatment)
Amikacin
Bedaquiline
Clofazimine
Cycloserine
Delamanid
Ethambutol
Ethionamide
Isoniazid
Linezolid
Moxifloxacin
Pretomanid
Pyrazinamide
Rifampicin
Drug
BPaLM INCREASES time with TB disease resistant to drug, compared to SOC
BPaLM DECREASES time with TB disease resistant to drug, compared to SOC


Productivity Loss
from Early Mortality
Indirect
Direct Nonmedical
Direct Medical
Cost Category
0
2500
5000
7500
10000
12500
Undiscounted Cost (2022 USD)
Strategy
(1): 6 months BPaLM
(7): Standard of Care